Mary Wilson
New member
Published: April 13, 2021
DOI:https://doi.org/10.1016/S2666-5247(21)00082-3
Baoying Huang, Lianpan Dai, Hui Wang, Zhongyu Hu, Xiaoming Yang, Wenjie Tan, George F Gao
BBIBP-CorV and ZF2001 are two COVID-19 vaccines developed in China. BBIBP-CorV is an inactivated virus vaccine approved for conditional marketing authorisation[SUP]1[/SUP] and ZF2001 is a recombinant dimeric receptor-binding domain (RBD) protein vaccine currently in phase 3 clinical trials and approved for emergency use in China and Uzbekistan.[SUP]2[/SUP][SUP], [/SUP] [SUP]3[/SUP] Both vaccines showed good immunogenicity in phase 1 and 2 trials.[SUP]1[/SUP][SUP], [/SUP] [SUP]3
...
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00082-3/fulltext[/SUP]
DOI:https://doi.org/10.1016/S2666-5247(21)00082-3
Baoying Huang, Lianpan Dai, Hui Wang, Zhongyu Hu, Xiaoming Yang, Wenjie Tan, George F Gao
BBIBP-CorV and ZF2001 are two COVID-19 vaccines developed in China. BBIBP-CorV is an inactivated virus vaccine approved for conditional marketing authorisation[SUP]1[/SUP] and ZF2001 is a recombinant dimeric receptor-binding domain (RBD) protein vaccine currently in phase 3 clinical trials and approved for emergency use in China and Uzbekistan.[SUP]2[/SUP][SUP], [/SUP] [SUP]3[/SUP] Both vaccines showed good immunogenicity in phase 1 and 2 trials.[SUP]1[/SUP][SUP], [/SUP] [SUP]3
...
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00082-3/fulltext[/SUP]